Cormedix (STU:19KA) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:19KA Cormedix Inc STU:19KA
40 GF Score
Price €6.93
! 6 Warning Signs
View Full Analysis

What is Cormedix Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:19KA
40GF Score
Cormedix Inc STU:19KA
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cormedix Business Description

Other Exchanges CRMD:USA
Address 389 Interpace Parkway, Suite 450, Parsippany, NJ, USA, 07054
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
40GF Score

Get the complete analysis for STU:19KA

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.93
Price